BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22818416)

  • 1. A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.
    Martin LK; Grecula J; Jia G; Wei L; Yang X; Otterson GA; Wu X; Harper E; Kefauver C; Zhou BS; Yen Y; Bloomston M; Knopp M; Ivy SP; Grever M; Bekaii-Saab T
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e475-81. PubMed ID: 22818416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
    Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
    Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
    Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
    Gojo I; Tidwell ML; Greer J; Takebe N; Seiter K; Pochron MF; Johnson B; Sznol M; Karp JE
    Leuk Res; 2007 Sep; 31(9):1165-73. PubMed ID: 17324462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
    Schelman WR; Morgan-Meadows S; Marnocha R; Lee F; Eickhoff J; Huang W; Pomplun M; Jiang Z; Alberti D; Kolesar JM; Ivy P; Wilding G; Traynor AM
    Cancer Chemother Pharmacol; 2009 May; 63(6):1147-56. PubMed ID: 19082825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
    Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
    Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
    J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
    Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study.
    Sunyach MP; Penel N; Montané L; Cassier PA; Largo AC; Sargos P; Blanc E; Pérol D; Blay JY
    Radiother Oncol; 2022 Mar; 168():95-103. PubMed ID: 35065999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel as a radiation sensitizer for locally advanced gastric and pancreatic cancers: the Brown University Oncology Group experience.
    Sikov WM; Safran H
    Front Biosci; 1997 May; 2():e21-7. PubMed ID: 9206986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction.
    Safran H; Akerman P; Cioffi W; Gaissert H; Joseph P; King T; Hesketh PJ; Wanebo H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):53-7. PubMed ID: 10210540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
    Koukourakis MI; Giatromanolaki A; Schiza S; Kakolyris S; Georgoulias V
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(1):107-14. PubMed ID: 9989521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas.
    Tedesco KL; Berlin J; Rothenberg M; Choy H; Wyman K; Scott Pearson A; Daniel Beauchamp R; Merchant N; Lockhart AC; Shyr Y; Caillouette C; Chakravarthy B
    Radiother Oncol; 2005 Jul; 76(1):54-8. PubMed ID: 15921772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
    Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study.
    Gridelli C; Guida C; Barletta E; Gatani T; Fiore F; Barzelloni ML; Rossi A; de Bellis M; D'Aniello R; Scognamiglio F
    Lung Cancer; 2000 Aug; 29(2):131-7. PubMed ID: 10963843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer--results from a Phase I trial.
    Hoffmann W; Belka C; Schmidberger H; Budach W; Bochtler H; Hess CF; Bamberg M
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):691-6. PubMed ID: 9240634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
    Karp JE; Giles FJ; Gojo I; Morris L; Greer J; Johnson B; Thein M; Sznol M; Low J
    Leuk Res; 2008 Jan; 32(1):71-7. PubMed ID: 17640728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer.
    Robertson JM; Ensminger WD; Walker S; Lawrence TS
    Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):331-5. PubMed ID: 9069304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel and simultaneous radiation in locally advanced stage IIIA/B non-small cell lung cancer: a clinical phase I study.
    Vogt HG; Kolotas C; Martin T; Schneider LV; Goes-Schmieder R; Mitrou PS; Diergarten K; Kober B; Zamboglou N
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):120-3. PubMed ID: 9007138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.